Stock Alert:

(NASDAQ: CVKD)

Add This Stock to Your Watchlist Immediately — Here’s Why

Cadrenal (CVKD) combines FDA support, a relationship with Abbott, and a Phase 3-ready treatment aimed at high-risk heart patients. Many investors haven’t spotted it yet — this could be your chance to follow early.

Full breakdown below.

logologologologologo
smsEnter your phone number
investors

The fastest-growing community for timely stock market moves.

arrow

*Sponsored

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD)

Moving Toward a Trial That Could Make a Difference for Patients — and Catch the Eye of Tactical Investors

Have you ever scrolled through “best stocks to watch” lists, hoping to find a biotech company making real progress toward solving a serious health problem? Cadrenal Therapeutics may be worth adding to your watchlist.

The Company in Focus

Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing Tecarfarin, an investigational oral anticoagulant designed for patients with end-stage kidney disease (ESKD) and those with mechanical circulatory support devices like Left Ventricular Assist Devices (LVADs).

Why this matters:

  • Many anticoagulants are cleared primarily by the kidneys, which can be problematic for patients with advanced kidney disease.
  • Tecarfarin is designed to be metabolized by the liver, potentially avoiding kidney-related dosing challenges.
  • If successful in clinical trials, Tecarfarin could offer an alternative for patients with limited treatment options.

Two High-Need Patient Populations

1. End-Stage Kidney Disease (ESKD) + Atrial Fibrillation

Patients with ESKD are at increased risk of stroke and systemic embolism, but treatment options remain limited. Cadrenal is planning a Phase 3 trial to evaluate Tecarfarin’s safety and effectiveness in reducing these risks in this population.

2. LVAD Patients

LVADs can sustain life in advanced heart failure patients, but clot-related complications remain a concern. Tecarfarin has received Orphan Drug Designation for use in this patient group, which may provide certain regulatory incentives if the drug is approved.

Regulatory Status

According to the company’s public filings and announcements:

  • Orphan Drug Designation (ODD) has been granted for Tecarfarin in both LVAD patients and ESKD patients with atrial fibrillation.
  • Fast Track Designation has been granted for Tecarfarin in ESKD patients with atrial fibrillation, enabling more frequent interaction with the FDA during development.

These designations do not imply approval or guarantee success. They are intended to support the development process for serious or rare conditions.

Recent Milestones

  • May 2025 - Announced plans for a pivotal Phase 3 trial in ESKD patients transitioning to dialysis.
  • March 2025 - Reported manufacturing progress for Tecarfarin to support trial readiness.
  • February 2025 - Entered into a collaboration with Abbott to support Tecarfarin’s LVAD program using the HeartMate 3 system.
  • April 2025 - Presented research on anticoagulation challenges in LVAD patients.

Want updates like this sent directly to you?

Get company news, filings, and alerts sent straight to your inbox and phone.

Sign up here.

Stockverse.com/newsletter

Market Context

ESKD + AFib – More than 500,000 people in the U.S. live with ESKD, with atrial fibrillation more common in this group than in the general population.

LVAD – Thousands of devices are implanted annually, with anticoagulation therapy required to help prevent clot-related events.

Why Some Investors Are Watching

  • Upcoming Phase 3 trial — an important milestone for a clinical-stage biotech.
  • Regulatory designations — may offer development incentives.
  • Abbott collaboration — alignment with a major player in cardiovascular devices.
  • Unmet need — targeting two patient populations with limited therapeutic options.

Key Definitions for New Readers

  • Phase 3 Trial: A late-stage clinical study to evaluate safety and effectiveness, often required before submitting for FDA review.
  • Orphan Drug Designation: FDA status that can provide benefits like market exclusivity upon approval for rare conditions.
  • Fast Track Designation: Designed to speed the review process for drugs treating serious conditions with unmet needs.
  • LVAD: A mechanical pump that supports heart function in advanced heart failure patients.

Bottom Line

Cadrenal Therapeutics (NASDAQ: CVKD) is advancing toward a planned late-stage clinical trial for Tecarfarin, a drug candidate targeting patient groups with pressing medical needs. While there is no guarantee of trial success or FDA approval, the company’s recent progress, regulatory designations, and partnership with Abbott may keep it on the radar for those following developments in biotech.

STOCK INFORMATION

neov

Cadrenal Therapeutics, Inc.

CVKD neov Nasdaq Stock Market

February 26

Upcoming Earnings

EPS

Market cap

USD (%)

Market Closed (as of 06:29 GMT+5:30)

Add CVKD to your watchlist today

3333

― Join StockVerse Alerts Today!

Winning Stock Picks Sent To Inbox

Sign up for our newsletter to receive the latest updates, insights, and exclusive Winning Stock Picks. As of 2024, our alerts are up a total of 873.22%.

— Your Next Winning Stock Awaits!

Grow Your Wealth by +673.66%! Sign Up Now for Exclusive Stock Picks and Alerts

Phone

By submitting this form and signing up for texts, you consent to receive marketing text messages (e.g., promos, cart reminders) from Relqo Media at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms.

american-flagUSA

1309 coffeen ave suite 1200

sheridan wyoming 84403
www.stockverse.com

— Follow Us

imgStockverse Logo
close

Missed Tesla? Nvidia? Don’t Miss This One.

Get our next breakout stock alert — sent directly to your inbox. Free, fast, and backed by real data.

No spam. Unsubscribe anytime.

Phone

By submitting this form and signing up for texts, you consent to receive marketing text messages (e.g., promos, cart reminders) from Relqo Media at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms.

MASTER LEGAL DISCLAIMER

Effective Date: August 2024

Last Updated: Aug 4, 2025

Publisher: Relqo Media LLC (Wyoming, United States)

Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

IMPORTANT SUMMARY — PLEASE READ FIRST

This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Genesis One Holdings LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

1. NATURE AND INTENT OF THIS COMMUNICATION

Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.

2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

Relqo Media LLC has been retained by Genesis One Holdings LLC to provide promotional media services for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). As of the effective date:

  • Relqo Media LLC received cash compensation for digital investor awareness campaigns at a rate of $25,000 per week, paid weekly, for the period beginning January 1, 2025, through July 1, 2025, totaling $650,000.
  • A renewal agreement was executed for continued services at the same weekly rate, covering June 26, 2025, through July 26, 2025, totaling an additional $100,000.
  • As of July 26, 2025, Relqo Media LLC continues to be retained weekly by Genesis One Holdings LLC at $25,000 per week, paid weekly. This ongoing compensation remains in effect until further notice.
  • Genesis One Holdings LLC may own, acquire, or dispose of shares of CVKD before, during, or after the campaign period.

This relationship creates a material conflict of interest. All content distributed by Relqo Media LLC regarding CVKD should be viewed as promotional, financially motivated, and inherently biased.

3. INTENDED AUDIENCE

These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

Relqo Media LLC does not independently verify, investigate, or audit any statements made by the company being promoted, its officers, its press releases, or any third-party sources. Any claims, projections, customer announcements, or product statements made in connection with CVKD should be assumed to be unverified and potentially inaccurate unless independently confirmed. You should not rely on any statements regarding future performance, partnerships, revenue projections, or corporate plans.

5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

Promotional campaigns commonly result in short-lived spikes in stock price and volume, followed by rapid declines. These spikes are typically driven by retail speculation, promotional circulation, and momentary investor interest—not fundamentals. You should expect that:

  • CVKD’s stock may increase temporarily during this promotion,
  • Trading volume may rise sharply, and
  • The price may fall after the campaign ends or selling begins.

These patterns are typical of stock promotions, and you should proceed accordingly.

6. NO RELIANCE – INVESTOR RESPONSIBILITY

The burden of research, investigation, and risk assessment rests solely with you. Relqo Media LLC is not responsible for your investment decisions. You are strongly urged to:

  • Read public filings from the SEC,
  • Consult a licensed financial adviser,
  • Understand risks such as dilution, insider selling, and volatility, and
  • Recognize that speculative stocks often lack financial transparency.

We accept no responsibility for losses incurred due to actions taken based on our Communications.

7. FORWARD-LOOKING STATEMENTS AND SAFE HARBOR

Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about potential growth, revenue forecasts, market opportunity, strategic partnerships, or technological development. Such statements are speculative and based on assumptions that may never occur. Actual results may differ materially. These statements are made under the safe harbor protections of Sections 27A and 21E of the Securities Acts. Relqo Media disclaims any duty to update them.

8. INFORMATION SOURCING, BIAS, AND ACCURACY

We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

Assume all information presented by Relqo Media is:

  • Subjective,
  • Not independently verified,
  • Created to highlight potential upside and omit downsides,
  • Not suitable as the basis for any investment decision.

9. OWNERSHIP AND TRADING CONFLICTS

Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

We use a range of outreach and promotional tools, including:

  • Email and newsletter distributions,
  • SMS/MMS text campaigns,
  • Social media posts and influencers,
  • Google and native display ads,
  • Press releases, video marketing, and paid content distribution.

By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

11. ADVERTISING LAW COMPLIANCE

Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

We make good-faith efforts to disclose all:

  • Compensation arrangements,
  • Conflicts of interest,
  • Risks,
  • Limitations of our role, and
  • The promotional nature of this content.

We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

12. NON-U.S. USERS

This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

  • Investment losses,
  • Inaccuracies,
  • Technical delays,
  • User misunderstandings,
  • Omissions or errors in content.

Total liability for any claim shall not exceed one hundred dollars ($100).

14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

16. FINAL NOTICE – ACCEPTANCE OF TERMS

We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

If you do not accept all terms of this disclaimer in full, you must:

  • Exit our websites,
  • Unsubscribe from our communications,
  • Discontinue viewing all Relqo Media promotional content.

17. NO RELIANCE

By viewing or engaging with this content, you agree that:

  • You will not rely on any statements made by Relqo Media for investment purposes,
  • You waive any claim that our content was a material factor in your investment decision,
  • You have read, understood, and accepted this disclaimer in full.

© 2024 Relqo Media LLC. All Rights Reserved.

Legal Contact: 📧 support@stockverse.com

Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

Affiliate Disclosure: Relqo Media LLC owns and operates Stockverse.com and all affiliated digital properties.